Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients (Q33413428)

26 July 2017

title

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients (English)

1 reference

myeloproliferative neoplasm

26 July 2017

main subject

1 reference

based on heuristic

inferred from title

author

Jean-Jacques Kiladjian

object named as

Jean-Jacques Kiladjian

0 references

Francesco Passamonti

0 references

Konstanze Döhner

1 reference

26 July 2017

Amylou C Dueck

1 reference

26 July 2017

Sonja Zweegman

1 reference

26 July 2017

Alessandro Rambaldi

1 reference

26 July 2017

Tiziano Barbui

1 reference

26 July 2017

Holly L Geyer

1 reference

26 July 2017

Robyn M Scherber

1 reference

26 July 2017

Zhijian Xiao

1 reference

26 July 2017

Stefanie Slot

1 reference

26 July 2017

Federico Sackmann

1 reference

26 July 2017

Ana Kerguelen Fuentes

1 reference

26 July 2017

Dolores Hernández-Maraver

1 reference

26 July 2017

Claire N Harrison

1 reference

26 July 2017

Deepti Radia

1 reference

26 July 2017

Pablo Muxi

1 reference

26 July 2017

Carlos Besses

1 reference

26 July 2017

Francisco Cervantes

1 reference

26 July 2017

Peter L Johansson

1 reference

26 July 2017

Bjorn Andreasson

1 reference

26 July 2017

Alessandro M Vannucchi

1 reference

26 July 2017

Jan Samuelsson

1 reference

26 July 2017

Gunnar Birgegard

1 reference

26 July 2017

Ruben A Mesa

1 reference

26 July 2017

language of work or name

English

0 references

publication date

19 February 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

123

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

3803-3810

1 reference

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Mutation in TET2 in myeloid cancers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Mutations of ASXL1 gene in myeloproliferative neoplasms.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067502

Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24553173

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24553173

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2013-09-527903

1 reference

26 July 2017

1 reference

26 July 2017

1 reference